Primary Outcome Measures:Change in

Primary Outcome Measures:
Change in number of terminal hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of terminal hair follicles over the treatment period.

Change in number of anagen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of anagen hair follicles over the treatment period.

Change in number of telogen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of telogen hair follicles over the treatment period.

Change in number of catagen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of catagen hair follicles over the treatment period.

Change in number of vellus (vellus-like) miniaturized hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of vellus (vellus-like) miniaturized hair follicles over the treatment period.

Change in number of indeterminate hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of indeterminate hair follicles over the treatment period.

Secondary Outcome Measures:
Change in number of terminal hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of terminal hair follicles over the treatment and off-treatment periods.

Change in number of anagen hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of anagen hair follicles over the treatment and off-treatment periods.

Change in number of telogen hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of telogen hair follicles over the treatment and off-treatment periods.

Change in number of catagen hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of catagen hair follicles over the treatment and off-treatment periods.

Change in number of vellus (vellus-like) miniaturized hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of vellus (vellus-like) miniaturized hair follicles over the treatment and off-treatment periods.

Change in number of indeterminate hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of indeterminate hair follicles over the treatment and off-treatment periods.

Change in density of hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in density of hair follicles over the treatment and off-treatment periods.

Ratio of terminal to miniaturized hair follicles (indeterminate hair and vellus hair follicles) [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be used to determine the ratio of terminal to miniaturized hair follicles during the treatment and off-treatment

Change in number of anagen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of anagen hair follicles over the treatment period.

Change in number of telogen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of telogen hair follicles over the treatment period.

Change in number of catagen hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of catagen hair follicles over the treatment period.

Change in number of vellus (vellus-like) miniaturized hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of vellus (vellus-like) miniaturized hair follicles over the treatment period.

Change in number of indeterminate hair follicles [ Time Frame: Baseline and Day 91 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy and after 90 days of therapy will be compared to determine the change in number of indeterminate hair follicles over the treatment period.

Secondary Outcome Measures:
Change in number of terminal hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of terminal hair follicles over the treatment and off-treatment periods.

Change in number of anagen hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of anagen hair follicles over the treatment and off-treatment periods.

Change in number of telogen hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of telogen hair follicles over the treatment and off-treatment periods.

Change in number of catagen hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of catagen hair follicles over the treatment and off-treatment periods.

Change in number of vellus (vellus-like) miniaturized hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of vellus (vellus-like) miniaturized hair follicles over the treatment and off-treatment periods.

Change in number of indeterminate hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in the number of indeterminate hair follicles over the treatment and off-treatment periods.

Change in density of hair follicles [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be compared to determine the change in density of hair follicles over the treatment and off-treatment periods.

Ratio of terminal to miniaturized hair follicles (indeterminate hair and vellus hair follicles) [ Time Frame: Baseline, Day 91 and Day 135 ] [ Designated as safety issue: No ]
Scalp biopsies obtained prior to initiating therapy, after 90 days of therapy, and after an additional 45 days off therapy will be used to determine the ratio of terminal to miniaturized hair follicles during the treatment and off-treatment

0/5000

原始語言: -

目標語言: -

結果 (中文) 1: [復制]

復制成功！

主要观察指标:在终端毛囊数目变化 [时间框架: 基线和天 91] [指定为安全问题: 无]头皮活检获得开始治疗之前和之后 90 天的治疗将比较来确定人数的终端毛囊在治疗期间的变化。在生长期毛囊数目变化 [时间框架: 基线和天 91] [指定为安全问题: 无]头皮活检获得开始治疗之前和之后 90 天的治疗将进行比较以确定人数的生长期毛囊在治疗期间的变化。休止期的毛囊数量变化 [时间框架: 基线和天 91] [指定为安全问题: 无]头皮活检获得开始治疗之前和之后 90 天的治疗将进行比较以确定人数的休止期的毛囊在治疗期间的变化。毛发的毛囊数量变化 [时间框架: 基线和天 91] [指定为安全问题: 无]头皮活检获得开始治疗之前和之后 90 天的治疗将比较来确定人数的毛发毛囊在治疗期间的变化。毳 (毳样) 人数变化小型化毛囊 [时间框架: 基线和天 91] [指定为安全问题: 无]头皮活检获得开始治疗前和治疗 90 天后将进行比较以确定人数毳 (毳样) 毛囊在治疗期间的变化。超静定毛囊数量变化 [时间框架: 基线和天 91] [指定为安全问题: 无]头皮活检获得开始治疗之前和之后 90 天的治疗将进行比较以确定人数不定毛囊在治疗期间的变化。二次结果的措施:在终端毛囊数目变化 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]将对比头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得过度治疗和治疗结束后时期确定终端毛囊数目的变化。在生长期毛囊数目变化 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]将对比头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得过度治疗和治疗结束后时期确定的生长期毛囊数量的变化。休止期的毛囊数量变化 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]将对比头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得过度治疗和治疗结束后时期确定的休止期的毛囊数量的变化。毛发的毛囊数量变化 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]将对比头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得过度治疗和治疗结束后时期确定的毛发毛囊数量的变化。毳 (毳样) 人数变化小型化毛囊 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]将对比头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得过度治疗和治疗结束后时期确定毳 (毳样) 毛囊数目的变化。超静定毛囊数量变化 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]将对比头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得过度治疗和治疗结束后时期确定不确定毛囊数目的变化。在毛囊密度变化 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]将对比头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得确定的变化在毛囊密度过度治疗和治疗结束后时期。终端对毛囊 (不定的头发和毳毛囊) 比 [时间框架: 基线、 91 天和一天 135] [指定为安全问题: 无]头皮活检前开始治疗，经过 90 天的治疗，和额外的 45 天假治疗后取得将用于治疗和治疗结束后期间确定的终端小型化的毛囊比例

正在翻譯中..

結果 (中文) 2:[復制]

復制成功！

正在翻譯中..

結果 (中文) 3:[復制]

復制成功！

正在翻譯中..

其它語言

本翻譯工具支援: 世界語, 中文, 丹麥文, 亞塞拜然文, 亞美尼亞文, 伊博文, 俄文, 保加利亞文, 信德文, 偵測語言, 優魯巴文, 克林貢語, 克羅埃西亞文, 冰島文, 加泰羅尼亞文, 加里西亞文, 匈牙利文, 南非柯薩文, 南非祖魯文, 卡納達文, 印尼巽他文, 印尼文, 印度古哈拉地文, 印度文, 吉爾吉斯文, 哈薩克文, 喬治亞文, 土庫曼文, 土耳其文, 塔吉克文, 塞爾維亞文, 夏威夷文, 奇切瓦文, 威爾斯文, 孟加拉文, 宿霧文, 寮文, 尼泊爾文, 巴斯克文, 布爾文, 希伯來文, 希臘文, 帕施圖文, 庫德文, 弗利然文, 德文, 意第緒文, 愛沙尼亞文, 愛爾蘭文, 拉丁文, 拉脫維亞文, 挪威文, 捷克文, 斯洛伐克文, 斯洛維尼亞文, 斯瓦希里文, 旁遮普文, 日文, 歐利亞文 (奧里雅文), 毛利文, 法文, 波士尼亞文, 波斯文, 波蘭文, 泰文, 泰盧固文, 泰米爾文, 海地克里奧文, 烏克蘭文, 烏爾都文, 烏茲別克文, 爪哇文, 瑞典文, 瑟索托文, 白俄羅斯文, 盧安達文, 盧森堡文, 科西嘉文, 立陶宛文, 索馬里文, 紹納文, 維吾爾文, 緬甸文, 繁體中文, 羅馬尼亞文, 義大利文, 芬蘭文, 苗文, 英文, 荷蘭文, 菲律賓文, 葡萄牙文, 蒙古文, 薩摩亞文, 蘇格蘭的蓋爾文, 西班牙文, 豪沙文, 越南文, 錫蘭文, 阿姆哈拉文, 阿拉伯文, 阿爾巴尼亞文, 韃靼文, 韓文, 馬來文, 馬其頓文, 馬拉加斯文, 馬拉地文, 馬拉雅拉姆文, 馬耳他文, 高棉文, 等語言的翻譯.